A 65-year-old Califonia woman died of the CPP Virus (COVID-19) not long after she received her second Moderna shot.
Napa County officials said that it was the state’s very first “break through” case.
The woman tested positive for the B.1.1.7 variant—which the World Health Organization (WHO) named “Alpha”—originally surfaced in the UK.
Napa County spokeswoman Leah Greenbaum revealed that the woman had underlying health conditions and passed away on June 2 after a lengthy hospital stay.
“Getting vaccinated helps protect us, and it helps protect vulnerable people who aren’t able to mount that immune response,” Greenbaum said at the news conference.
The B.1.17 variant appears to be more contagious and might create more severe symptoms once the person becomes infected.
“No vaccine is 100% effective, but this does not diminish the urgency and importance of getting vaccinated, especially as more variant strains emerge,” Napa County Public Health Officer Dr. Karen Relucio stated.
She also added that the vaccines “provide exceptional protection against death and illness.”
Over the past month, deaths and hospitalizations from infection with the CCP Virus have tripled in the United States among those fully vaccinated.
According to a data report released in late May by the Centers for Disease Control and Prevention (CDC), between January 1 and April 30, 2021, there were a total of 10,262 SARS-CoV-2 vaccines “breakthrough infections,” defined as coronavirus infections in fully vaccinated persons, from 46 U.S. states and territories.
Just days after the above report, the CDC website reported that 3,016 fully vaccinated patients with the COVID-19 vaccine had developed a “breakthrough infection” and had been hospitalized or died during May. COVID deaths of vaccinated patients totaled 535 as of June 1 compared with 160 deaths reported a month earlier.
Without explaining their decision, the CDC reported that as of May 1, it would only be counting cases and infections of the CCP Virus in vaccinated patients who end up hospitalized or die, discounting the nearly 90% of cases that are not hospitalized and do not die but do report vaccine failure.
The controversial move clarifies a major gap in data collection on vaccine efficacy exists, so future reported numbers will be completely skewed.